Sustainability is no longer just a goal, it’s a responsibility. The clinical research industry plays a vital role in advancing healthcare and improving patient outcomes, bringing the latest and best treatments closer to patients to enhance their life expectancy and quality of life. However, these advancements should not come at the expense of the environment or ethical business practices.
At APICES, we are committed to integrating eco-friendliness into our daily operations. Our dedication has been recognized with two key certifications:
CDP: This certification reflects our commitment to environmental transparency and reducing carbon emissions in our operations.
EcoVadis: A global environmental responsibility rating that evaluates our performance in environmental, social, and ethical aspects, ensuring we adhere to the highest corporate responsibility standards.
These certifications also demonstrate our commitment to transparency, reinforcing our ethical approach to clinical research and responsible business practices.
Sustainability is embedded in our work. Our entire team applies sustainable practices in their activities, ensuring that clinical research is conducted responsibly and with a long-term vision. By integrating sustainability into research processes, we contribute to a healthier future while maintaining the highest ethical and scientific standards.
At APICES, we believe that innovation and sustainability must go hand in hand to drive meaningful progress in clinical trials, always maintaining the highest quality standards. By integrating sustainable practices into our clinical research processes, we ensure that every study not only contributes to medical advancements but also respects the environment and ethical values. Our commitment to sustainability guides our work at every stage, from planning to execution, ensuring that we deliver reliable results while minimizing our ecological impact.
Contact us to carry out your clinical research projects with a partner committed to sustainability, transparency, and excellence.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
